Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Dr. Matthew Witkowski – University of Colorado Denver, AMC and DC
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Dr. Linda Resar – Johns Hopkins University School of Medicine, Baltimore, MD
Discovery of novel MDM2-targeted therapy for pediatric AML
Discovery of novel MDM2-targeted therapy for pediatric AML
Dr. Muxiang Zhou – Emory University, Atlanta, GA
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Dr. Zhaohui Gu – Beckman Research Institute of the City of Hope, Duarte, CA
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Beckman Research Institute of the City of Hope, Duarte, CA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
The Regents of the University of Michigan, Ann Arbor, MI
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Stanford University, Stanford, CA
Polycomb inhibition sensitizes AML to anthracycline therapy
Polycomb inhibition sensitizes AML to anthracycline therapy
The Research Institute at Nationwide Children’s Hospital, Columbus, OH
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
The Regents of the University of Michigan, Ann Arbor, MI
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Baylor College of Medicine, Houston, TX
Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics
Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics
Stanford University, Stanford, CA
Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia
Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia
Yale University, New Haven, CT
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric ALL CAR T-Cell Therapy
Pediatric ALL CAR T-Cell Therapy
Seattle Children’s Hospital, Seattle, WA
Epigenetic Therapy in AML
Epigenetic Therapy in AML
Nemours/A.I. DuPont Hospital, Wilmington, DE
Reversing NK Cell Dysfunction in Pediatric Cancer
Reversing NK Cell Dysfunction in Pediatric Cancer
Case Western Reserve University, Cleveland, OH
Zebrafish Models of Human AML
Zebrafish Models of Human AML
Dana-Farber/Harvard Medical Center, Boston, MA